PDCD1 and neoplasm: The need for alternative strategies aimed at interfering with the negative regulators of anti-tumour immunity prompted the development of immune checkpoint blocking agents, such as monoclonal antibodies against key immunosuppressive molecules including cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein-1 (PD-1).